
MMSI Stock Forecast & Price Target
MMSI Analyst Ratings
Bulls say
Merit Medical Systems is expected to continue its growth through new product launches and acquisitions, as well as its Continued Growth Initiatives program. With an expected organic revenue growth of 6-8%, and a strong balance sheet, the company is well-positioned for future success and potential M&A opportunities. While there is some risk involved in terms of margin performance and slower growth in China, the company's disciplined approach to M&A should mitigate these risks. Overall, the outlook for Merit Medical Systems is positive, with a base case scenario of a 6-8% organic revenue growth and a potential bull case scenario of 9% or higher growth.
Bears say
Merit Medical Systems is currently facing significant challenges with their Cardiovascular segment, as the majority of their revenue is earned from this segment and the recent acquisitions may not be able to drive above-corporate average growth. Additionally, the company's free cash flow has seen a decline in recent years and their net leverage ratio remains high, potentially limiting their ability to invest in growth opportunities. Furthermore, while the launch of the WRAPSODY Cell-Impermeable Endoprosthesis may contribute to revenue growth and margins, it is uncertain how well the product will perform in the market and if it will meet company expectations.
This aggregate rating is based on analysts' research of Merit Medical Systems and is not a guaranteed prediction by Public.com or investment advice.
MMSI Analyst Forecast & Price Prediction
Start investing in MMSI
Order type
Buy in
Order amount
Est. shares
0 shares